Frontlight ResearchEarly access
CompletedPhase 4
Dexamethasone With Ropivacaine for PENG Block in Total Hip Arthroplasty
Key facts
- Who runs it
- Poznan University of Medical Sciences
- Where
- Poland1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 60 people enrolled
- Started
- 7 Nov 2024
- Ended
- 30 Apr 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Ropivacaine
- Ropivacaine+Dexamethasone
- Record updated
- 11 July 2025
Who can take part
- Age
- 65 years to 100 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- patients scheduled for total hip arthroplasty
- patients aged >65 and <100 years
- patients able to provide informed consent
- patients able to reliably report symptoms to the research team
Who cannot take part
- inability to provide first-party consent due to cognitive impairment or a language barrier
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Does adding Dexamethasone to the Periarticular Nerve Group Block in Patients undergoing Total Hip Arthroplasty reduce the dose of ropivacaine?
The 2 groups in the trial
- RopivacaineExisting treatment, for comparison
Ultrasound-guided PENG block - 20ml 0,2% ropivacaine
- Ropivacaine + DexamethasoneExisting treatment, for comparison
Ultrasound-guided PENG block - 10ml 0,2% ropivacaine + 4mg Dexamethasone
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Pericapsular Nerve Group Block With 20 ml 0.2% Ropivacaine vs 10ml 0.2% Ropivacaine and Dexamethasone in Total Hip Arthroplasty: A Randomized Controlled Trial
- Record updated
- 11 July 2025